CS
DNTH icon

Candriam SCA’s Dianthus Therapeutics DNTH Stock Holding History

Candriam SCA’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Sell
204,214
-9,308
-4% -$813K 0.09% 202
2026
Q1 		$17.9M Sell
213,522
-97,628
-31% -$5.65M 0.09% 209
2025
Q4 		$12.8M Buy
311,150
+9,722
+3% +$377K 0.06% 238
2025
Q3 		$11.9M Buy
301,428
+60,852
+25% +$1.56M 0.06% 251
2025
Q2 		$4.48M Sell
240,576
-8,034
-3% -$151K 0.03% 371
2025
Q1 		$4.51M Buy
+248,610
New +$5.48M 0.03% 349

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Candriam SCA's DNTH Position: Q2 2026 in Review

Candriam SCA reduced its Dianthus Therapeutics (DNTH) stake by 4.4% in Q2 2026, selling an estimated $813K and leaving 204,214 shares worth $19.9M. The position accounts for 0.09% of the portfolio, ranked #202.

Candriam SCA first reported a position in DNTH in Q1 2025 and has held it in 6 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Candriam SCA held 204,214 shares of Dianthus Therapeutics worth $19.9M as of Q2 2026.
  • Candriam SCA sold 9,308 Dianthus Therapeutics shares in Q2 2026, an estimated $813K.
  • Dianthus Therapeutics made up 0.09% of Candriam SCA's portfolio in Q2 2026, its #202 holding.
  • Candriam SCA first reported a position in Dianthus Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.